In the first half of 2026, China's innovative drug business development (BD) overseas transactions surged to $99.7 billion, doubling from 2024 and reaching 73% of 2025's total. The upfront payments for BD external licensing alone amounted to approximately $5 billion, already representing 70% of last year's total. Industry experts anticipate that the full-year BD transaction value will set a new record, driven by multi-billion dollar deals, bulk purchases by multinational pharmaceutical companies, and the rise of co-development commercialization models, signaling a significant advancement for China's innovative drugs on the global stage. AI
IMPACT This surge in pharmaceutical BD deals may indicate increased investment in AI-driven drug discovery and development.
RANK_REASON The cluster reports on a significant financial milestone for China's innovative drug industry with substantial transaction values and growth. [lever_c_demoted from significant: ic=1 ai=0.4]
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
